Product Description
Autolus is developing a T-cell therapy targeting CD33, CD123, and CLL1 for the treatment of Acute Myeloid Leukemia. (Sourced from: https://www.autolus.com/media/e4al2yhk/q2-2023-ppt-final-3-8-23.pdf)
Mechanisms of Action: CAR-T,CD33,CD123,CLL1
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Autolus Limited
Company Location: LONDON X0 W12 7RZ
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for AUTO-9](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|